NASDAQ:KZR - Kezar Life Sciences Stock Price, News, & Analysis

Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR."

Kezar Life Sciences Inc (NASDAQ:KZR) released its quarterly earnings results on Thursday, November, 8th. The company reported ($0.30) earnings per share for the quarter, beating analysts' consensus estimates of ($0.48) by $0.18. View Kezar Life Sciences' Earnings History.

4 brokers have issued 1-year target prices for Kezar Life Sciences' shares. Their predictions range from $23.00 to $30.00. On average, they expect Kezar Life Sciences' stock price to reach $26.50 in the next twelve months. This suggests a possible upside of 20.7% from the stock's current price. View Analyst Price Targets for Kezar Life Sciences.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kezar Life Sciences.

Headlines about KZR stock have trended neutral this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kezar Life Sciences earned a daily sentiment score of 0.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near term.

Some companies that are related to Kezar Life Sciences include Myovant Sciences (MYOV), Theravance Biopharma (TBPH), Innoviva (INVA), Prestige Consumer Healthcare (PBH), Allakos (ALLK), Aimmune Therapeutics (AIMT), Nabriva Therapeutics (NBRV), Clovis Oncology (CLVS), Uniqure (QURE), TherapeuticsMD (TXMD), Corcept Therapeutics (CORT), Spectrum Pharmaceuticals (SPPI), Cambrex (CBM), Esperion Therapeutics (ESPR) and Phibro Animal Health (PAHC).

(KZR) raised $70 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair acted as the underwriters for the IPO.

Kezar Life Sciences' lock-up period expired on Tuesday, December 18th. Kezar Life Sciences had issued 5,000,000 shares in its public offering on June 21st. The total size of the offering was $75,000,000 based on an initial share price of $15.00. Since the expiration of Kezar Life Sciences' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

Kezar Life Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BB Biotech AG (4.28%), BlackRock Inc. (1.29%), Victory Capital Management Inc. (1.19%), Geode Capital Management LLC (0.30%), Northern Trust Corp (0.30%) and Sphera Funds Management LTD. (0.10%). Company insiders that own Kezar Life Sciences stock include Franklin M Berger and Morningside Venture Investment. View Institutional Ownership Trends for Kezar Life Sciences.

KZR stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc. and Sphera Funds Management LTD.. View Insider Buying and Selling for Kezar Life Sciences.

KZR stock was bought by a variety of institutional investors in the last quarter, including BB Biotech AG, Geode Capital Management LLC, Bank of New York Mellon Corp, Slow Capital Inc., Northern Trust Corp, BlackRock Inc. and New York State Common Retirement Fund. Company insiders that have bought Kezar Life Sciences stock in the last two years include Franklin M Berger and Morningside Venture Investment. View Insider Buying and Selling for Kezar Life Sciences.

Shares of KZR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of KZR stock can currently be purchased for approximately $21.96.

Kezar Life Sciences has a market capitalization of $419.61 million. Kezar Life Sciences employs 20 workers across the globe.

The official website for Kezar Life Sciences is http://www.kezarlifesciences.com.

Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-822-5600 or via email at [email protected]